Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M
Department of Oncology, Flow Cytometry Unit, Istituto di Richerche Farmacologiche Marco Negri, Milan, Italy.
Cell Prolif. 2007 Dec;40(6):885-904. doi: 10.1111/j.1365-2184.2007.00469.x.
Trabectedin (ET-743, Yondelis) is a natural marine product, with antitumour activity, currently in phase II/III clinical trials. Previous studies have shown that cells hypersensitive to ultraviolet (UV)-rays because of nucleotide excision repair (NER) deficiency, were resistant to trabectedin. The purpose of this study was to investigate whether this resistance was associated with different drug-induced cell cycle perturbations.
An isogenic NER-proficient cellular system (CHO-AA8) and a NER-deficient one (CHO-UV-96), lacking functional ERCC-1, were studied. Flow cytometric assays showed progressive accumulation of cells in G2 + M phase in NER-proficient but not in NER-deficient cells. Applying a computer simulation method, we realized that the dynamics of the cell cycle perturbations in all phases were complex.
Cells exposed to trabectedin during G1 and G2 + M first experienced a G1 block, while those exposed in S phase were delayed in S and G2 + M phases but eventually divided. In the presence of functional NER, exit from the G1 block was faster; then, cells progressed slowly through S phase and were subsequently blocked in G2 + M phase. This G2 + M processing of trabectedin-induced damage in NER-proficient cells was unable to restore cell cycling, suggesting a difficulty in repairing the damage.
This might be due either to important damage left unrepaired by previous G1 repair, or that NER activity itself caused DNA damage, or both. We speculate that in UV-96 cells repair mechanisms other than NER are activated both in G1 and G2 + M phases.
曲贝替定(ET - 743,商品名Yondelis)是一种具有抗肿瘤活性的天然海洋产物,目前正处于II/III期临床试验阶段。先前的研究表明,因核苷酸切除修复(NER)缺陷而对紫外线(UV)敏感的细胞对曲贝替定具有抗性。本研究的目的是调查这种抗性是否与不同药物诱导的细胞周期扰动有关。
研究了一个等基因的NER功能正常的细胞系(CHO - AA8)和一个NER功能缺陷的细胞系(CHO - UV - 96),后者缺乏功能性ERCC - 1。流式细胞术分析显示,NER功能正常的细胞中细胞在G2 + M期逐渐积累,而NER功能缺陷的细胞则不然。应用计算机模拟方法,我们认识到细胞周期各阶段扰动的动态过程是复杂的。
在G1期和G2 + M期暴露于曲贝替定的细胞首先经历G1期阻滞,而在S期暴露的细胞在S期和G2 + M期延迟,但最终分裂。在存在功能性NER的情况下,从G1期阻滞中退出更快;然后细胞缓慢通过S期,随后被阻滞在G2 + M期。曲贝替定诱导NER功能正常的细胞损伤后的这种G2 + M期处理无法恢复细胞周期进程,提示损伤修复存在困难。
这可能是由于先前G1期修复留下的未修复的重要损伤,或者NER活性本身导致了DNA损伤,或者两者皆有。我们推测在UV - 96细胞中,除NER之外的其他修复机制在G1期和G2 + M期均被激活。